Statement by Mr. François Hollande, President of the Republic, on Hospital-University Institutes, in Paris on April 6, 2016.

France François Hollande · President of France

6 April 2016 · International Day of Hospital-University Institutes (IHU) · Brain and Spine Institute, Paris, France

Context
Hollande addressed the first International Day of IHUs at the Brain and Spine Institute in Paris on April 6, 2016, highlighting France's medical research achievements.
Main themes
Hospital-University Institutes (IHUs), translational research, medical innovation, French research excellence, university hospital centers, Future Investment Program, neuroscience, collaborative research, life sciences, patient-centered care, economic and industrial development, public health
Duration
~16 min
54th percentile
Words
1,889
54th percentile
Sentences
76
50th percentile
Readability
47
53rd percentile
Grade
12.9
55th percentile
Syntax
3.05
54th percentile
Vocabulary
2.35
83rd percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 34%34%
  • Economic 33%33%
  • Institutional 20%20%
  • Ceremonial 11%11%
  • Technological 3%3%
  • Geopolitical 0%0%
  • Environmental 0%0%
  • Not in focus 0%

76 sentences in 24 paragraphs

Madam and Sir, the ministers,

Mr. President of the Brain and Spine Institute who is hosting us today,

Gentlemen Presidents, Mr. Director General,

Mr. Commissioner General for Investment who, thanks to his interventions, allows me to highlight what has already been done and what is being prepared to be undertaken.

Ladies and Gentlemen,

I wanted to be present here for this first International Day of IHUs and in a particularly symbolic place, the Brain and Spine Institute, which is a jewel, among others, but a jewel of French research in the field of neuroscience.

Among you are doctors, caregivers, researchers, engineers, industrialists, professionals, and even financiers, all engaged in research to combat diseases. This is indeed the purpose of these meetings: to bring medical research closer to businesses, to ensure that we can also facilitate relationships between researchers, entrepreneurs, and academics, to allow us to showcase France's excellence in health and to demonstrate above all that in five years - which is very short, five years - the IHUs have established themselves as reference institutions, and reference institutions for our country, for Europe, and for the world.

The IHUs were born from a desire, that which Professor MARESCAUX articulated in two reports, in 2009 and 2010. In France, we have a culture of reports, but what is important is to translate this culture into action, into reality. That is what has happened. Professor MARESCAUX's intention was to energize collaborative research in the life sciences. But to translate this intention, means were also needed: those of the Future Investment Program, and 850 million euros have thus been mobilized for the IHUs.

Finally, the IHUs represent a model; this model is that of translational research, meaning a continuity that must go from the patient's bedside to the industrial valorization of results. Research is ultimately in this process, and all stages can enrich it. Everything starts from the patient, everything returns to the patient. It is by treating him that doctors help researchers illuminate the most fundamental questions, and it is then these advances that allow for improved care for patients.

The Brain and Spine Institute is an illustration of this since there is here, in this hospital of Pitié-Salpêtrière and in this institute, both a clinical investigation center, laboratories, and companies. It is this proximity that forges the links that unite all teams and allows start-ups to be created, medical innovations to emerge, and finally for these results to be transformed into treatments that can be provided to patients.

Each IHU, there are six, applies this principle in its field. There is the IHU-ICM that we are visiting today, there is the IHU ICAN in Paris, still at Salpêtrière, which deals with cardio-metabolic and nutritional pathologies. This subject is indeed at the heart of government actions, it is the fight against chronic obesity with all the known consequences. In Marseille, I have also had the presentation of Méditerranée Infection which responds to health crises; there is the IHU MIX-Surg in Strasbourg, where new generations of surgical instruments are being developed, and thanks to imaging, there can be a minimally invasive surgical procedure; I also had the opportunity to visit this institute. In Bordeaux, there is Liryc, which paves the way for new forms of assistance to address heart failure. Finally, there is Necker Hospital with IHU Imagine which takes care of genetic diseases.

The strength of the IHUs, we cannot repeat it enough, is to be backed by university hospital centers. In fact, in the name IHU, one can guess the CHU. Without the CHUs, there are no IHUs, and I want to return to what was perhaps Robert DEBRE's intuition at the beginning of the 1960s, when he conceived the university hospital centers and wanted, it took time to achieve this result, to bring together in one place patients, doctors, researchers, and students, in one entity.

The IHUs are foundations of scientific cooperation. They have their own status but must be fully integrated into the medical project of the university hospital centers. Just as they must appear as stakeholders in the projects of universities. Finally, these IHUs are also very closely linked to the other founding members who participated in their creation and even their establishment - I am thinking of INSERM and CNRS. It is this whole that makes it possible for there to be this success. This is how the IHUs fit into the centers of academic and scientific excellence that we want to be of global level because we believe that France's asset is its research. With what objectives? It is not simply in the name of academic excellence even if that could be enough, it is not simply for public health objectives which alone should mobilize us, but it is because we can also make it a factor of economic and industrial development and thus shine throughout the world.

The creation of the IHUs has undoubtedly enhanced the attractiveness of our laboratories. Indeed, what a researcher expects, regardless of their nationality, is to be able to work in an innovative place, to have access to the latest equipment, and to be among renowned teams. This is what we had to demonstrate, that is to say, attract talents while knowing how to keep ours to ensure that we can provide the best welcome to each other. In a word, it is to have this demand for excellence. It is an opportunity for France, it is also an asset and a strength for our health system. I have said it, it is an opportunity for our economy because we have in France a health industry that is particularly dynamic and that is a partner of the scientific and medical community. There can be no translational research without health industries; this health industry is composed of both very large companies and also many start-ups. Thus, in less than five years, thanks to the IHUs, nearly 22 start-ups have been created. Some have been presented to me, others not yet. We wanted to attract entrepreneurs, creators from around the world, provided they have a level of research and innovation that can have effects, not necessarily in the short term but in the medium term for our economy. One of these start-ups, BIOSERENITY, was selected for the global innovation competition and was able to raise 3 million euros last year. I also have in mind VISIBLE PATIENT, a company incubated in Strasbourg with mappings, 3D modeling that was presented to me for image-guided surgery.

These start-ups - and I could name all those I have been able to visit, even from afar - these start-ups need investments and therefore need investment funds. Large companies sometimes support them, but there are also funds that can also have the will to help these start-ups raise significant amounts for financing their investments. I know that this is also one of the objectives of this International Day of IHUs, in relation to the Alliance for Research and Innovation in Health Industries: to mobilize the entire community and thus allow these companies to find either clients or funders.

I want to salute the representatives of foreign companies who have come because they are also aware that there can be opportunities for installations here in France, and the government, represented here, is at the disposal of these companies or laboratories to facilitate their establishment. I encourage all investors to seize the opportunities offered by the IHUs and by this ecosystem that is being born.

Finally, I want to salute the French companies of all sizes that are with us today; I remind you that the health industry represents 75 billion euros in revenue, 200,000 direct employees, 100,000 indirect employees, and it is the second largest French exporter after aeronautics. We therefore clearly measure what health in France represents as protection, as hope even for our fellow citizens, what it also represents as assets for our industrial capacity.

These are the results that can already be shown after five years of the IHUs' existence. It was not enough to launch them, it was not even enough to finance them; it was necessary that those for whom there was this desire to make them work could seize this initiative. Practically all buildings have been inaugurated - those that have not been, I am at their disposal, but I believe there will be 6,000 square meters in Bordeaux in June, 13,000 square meters this summer in Strasbourg, 21,000 square meters in the fall in Marseille, and from this point of view, I feel called upon. It is now necessary to confirm all these launches.

The commitment of the General Commission for Investment spans ten years; it is very important that you have this visibility because it is a long-term commitment that has been made. That is why the six IHUs, because there is this funding, have been subjected to a mid-term evaluation under the auspices of an international jury.

I wish, this result being demonstrated, this success no longer needing to be proven, that the ministers - Minister of Social Affairs, Minister of Health, Minister of National Education and Higher Education - can now work with Louis SCHWEITZER, the Commissioner General for Investment, on the sustainability of the IHUs.

As part of what is called the Future Investment Program number 2, 345 million euros have been dedicated to a Biotech Health acceleration fund to support start-ups but also to finance the sector of life industries, pharmaceuticals, and biotechnology. The first files will be financed at the end of the year. This mechanism complements that of the IHUs.

We will soon launch the Future Investment Program number 3. This will be done this year, and we will thus have a new phase that will again allow for investments in the fields of health, biotechnology, and life sciences.

Ladies and Gentlemen, I am aware that by coming here, by looking at all the progress that has been made thanks to you, it is the medicine of tomorrow that is being developed in these IHUs; it is here that the economy of tomorrow, the technologies of tomorrow are also invented. The economy of life and its knowledge is a sector still full of prospects. We can thus continually push back the limits of what we can know and what we can treat.

The IHUs have fully succeeded in their challenge here in France: bringing together in one place researchers, caregivers, patients, bringing institutions closer together, and above all reducing the time that separates discovery from its applications. For us, it is a priority to ensure that as soon as there is innovation, and despite all the procedures that must be respected, there can be a minimum time that elapses so that this innovation can be immediately put at the service of patients. That is why the IHUs represent a model for research in France. At this moment, I think of the patients who are waiting with hope for the advances in research, who wonder if they will be treated, if the discoveries that are announced can apply to them. By coming here, I cannot completely reassure them, but I can tell them that everything is being done so that we can treat them even better and ensure that research in France can be supported in the service of the public good. Thank you.